Alpha 2.0
Login Register
» Authors » Zafar Malik

Zafar Malik

Explore the profile of Zafar Malik including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 864
Followers 0
Related Specialties
Oncology
Radiology
General Medicine
Top 10 Co-Authors
Alison Birtle
Simon Chowdhury
Emma Hall
Chris Parker
Isabel Syndikus
Joe M OSullivan
Vincent Khoo
Nicholas D James
Christopher Scrase
Miguel Panades
Published In
Int J Radiat Oncol Biol Phys
Lancet Oncol
BJU Int
Expert Rev Anticancer Ther
Rep Pract Oncol Radiother
Affiliations
Soon will be listed here.
Recent Articles
1.
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial
Rescigno P, Porta N, Finneran L, Riisnaes R, Figueiredo I, Carreira S, et al.
Eur J Cancer . 2024 May; 205:114103. PMID: 38729054
Background: PTEN loss and aberrations in PI3K/AKT signaling kinases associate with poorer response to abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC). In this study, we assessed antitumor activity...
2.
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
Attard G, Murphy L, Clarke N, Sachdeva A, Jones C, Hoyle A, et al.
Lancet Oncol . 2023 May; 24(5):443-456. PMID: 37142371
Background: Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we...
3.
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Houten R, Fleeman N, Mahon J, Chaplin M, Edwards K, Beale S, et al.
Pharmacoecon Open . 2023 Apr; 7(3):345-358. PMID: 37084172
The National Institute for Health and Care Excellence (NICE) provides guidance to improve health and social care in England and Wales. NICE invited Daiichi Sankyo to submit evidence for the...
4.
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data
Clarke C, Hunter R, Gabrio A, Brawley C, Ingleby F, Dearnaley D, et al.
PLoS One . 2022 Jun; 17(6):e0269192. PMID: 35653395
Adding abiraterone acetate (AA) plus prednisolone (P) to standard of care (SOC) improves survival in newly diagnosed advanced prostate cancer (PC) patients starting hormone therapy. Our objective was to determine...
5.
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial
Gilson C, Ingleby F, Gilbert D, Parry M, Atako N, Ali A, et al.
JCO Precis Oncol . 2022 Jan; 4:882-897. PMID: 35050761
Purpose: The STAMPEDE trial recruits men with newly diagnosed, high-risk, hormone-sensitive prostate cancer. To ascertain the feasibility of targeted next-generation sequencing (tNGS) and the prevalence of baseline genomic aberrations, we...
6.
Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial
Tree A, Griffin C, Syndikus I, Birtle A, Choudhury A, Graham J, et al.
Int J Radiat Oncol Biol Phys . 2022 Jan; 113(2):305-315. PMID: 35017008
Purpose: CHHiP is a randomized trial evaluating moderately hypofractionated radiation therapy for treatment of localized prostate cancer. Of all participants, 97% of them had concurrent short-course hormone therapy (HT), either...
7.
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
Attard G, Murphy L, Clarke N, Cross W, Jones R, Parker C, et al.
Lancet . 2021 Dec; 399(10323):447-460. PMID: 34953525
Background: Men with high-risk non-metastatic prostate cancer are treated with androgen-deprivation therapy (ADT) for 3 years, often combined with radiotherapy. We analysed new data from two randomised controlled phase 3...
8.
Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)
Staffurth J, Haviland J, Wilkins A, Syndikus I, Khoo V, Bloomfield D, et al.
Eur Urol Oncol . 2021 Sep; 4(6):980-992. PMID: 34489210
Background: Moderate hypofractionation is the recommended standard of care for localised prostate cancer following the results of trials including Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer...
9.
Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry
Malik Z, Di Lorenzo G, Pichler A, De Giorgi U, Hitier S, Ecstein-Fraisse E, et al.
Cancers (Basel) . 2020 Apr; 12(4). PMID: 32316580
We examined factors that may impact cabazitaxel treatment duration in a real-life setting in a compassionate use program, expanded access program, and prospective observational study in metastatic castration-resistant prostate cancer...
10.
Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer
Fenwick J, Landau D, Baker A, Bates A, Eswar C, Garcia-Alonso A, et al.
Int J Radiat Oncol Biol Phys . 2019 Dec; 106(4):733-742. PMID: 31809876
Purpose: The IDEAL-CRT phase 1/2 multicenter trial of isotoxically dose-escalated concurrent chemoradiation for stage II/III non-small cell lung cancer investigated two 30-fraction schedules of 5 and 6 weeks' duration. We...